AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology.
It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics.
The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers.
It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury.
The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition.
It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department.
The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases.
It markets its products and services through its direct sales force and a network of distributors in the United States and internationally.
The company was founded in 1976 and is headquartered in New York, New York.
Country | United States |
IPO Date | Jun 12, 1980 |
Industry | Medical - Diagnostics & Research |
Sector | Healthcare |
Employees | 125 |
CEO | Kara Cannon |
Contact Details
Address: 527 Madison Avenue New York, New York United States | |
Website | https://www.enzo.com |
Stock Details
Ticker Symbol | ENZ |
Exchange | NYSE |
Fiscal Year | August - July |
Reporting Currency | USD |
CIK Code | 0000316253 |
CUSIP Number | 294100102 |
ISIN Number | US2941001024 |
Employer ID | 13-2866202 |
SIC Code | 8071 |
Key Executives
Name | Position |
---|---|
Kara Cannon | Chief Executive Officer & Director |
Patricia Eckert CPA | Chief Financial Officer |
Brian J. Fisher | General Counsel & Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 16, 2024 | 10-Q | Quarterly Report |
Dec 02, 2024 | 3 | Filing |
Nov 29, 2024 | ARS | Filing |
Nov 27, 2024 | DEF 14A | Filing |
Nov 25, 2024 | 8-K | Current Report |
Oct 30, 2024 | 8-K | Current Report |
Oct 29, 2024 | 10-K | Annual Report |
Sep 24, 2024 | 8-K | Current Report |
Aug 14, 2024 | 8-K | Current Report |
Aug 02, 2024 | 8-K | Current Report |